Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / AcelRx Pharmaceuticals saw big gains this past Friday after announcing third quarter results and an update on DSUVIA receiving FDA approval. Shares of Sage Therapeutics were halted after its treatment Zulresso, was recommended by an FDA approval...
AcelRx Pharmaceuticals (NASDAQ: ACRX ): Q3 GAAP EPS of -$0.21 misses by $0.01 . Revenue of $0.37M (-75.2% Y/Y) misses by $0.72M . Press Release More news on: AcelRx Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
REDWOOD CITY, Calif. , Nov. 2, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today provided a business update and reported its third quarter 2018...
REDWOOD CITY, Calif. , Nov. 2, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in a medically supervised setting, announced today the approva...
Over the past month AcelRx’s ( ACRX ) stock has experienced high volatility due to a looming FDA decision on the company’s lead drug DSUVIA. Typically a pending FDA approval decision generates a spike in volatility for the candidate’s stock; but ACRX’s story is ...
Editor's note: Seeking Alpha is proud to welcome NJ Biotech Expert as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Trevena...
AcelRx valuation sheet - click here to download. AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX ) stock recently jumped after a positive Adcom. ACRX now shows over 95 percent improvement this year so far. However, a number of key people have questioned the addition potential of this highl...
October 25, 2018 Palm Beach, FL – (October 25, 2018) – Cancer has a major impact on the health and well being of individuals across the globe. Cancer is identified as one of the leading causes of death worldwide. In 2017, approximately 0.5% of the world’s population ...
On October 12, AcelRx (NASDAQ: ACRX ) received positive news - an FDA Advisory Committee had voted 10-3 in favor of recommending that the FDA issue official approval for ACRX's lead drug candidate Dsuvia. Despite this, as I noted in my last ACRX article , the company's stock has yet to regis...
President Trump signs the STOP Act today, sweeping bipartisan legislation aimed at addressing the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...